HIGHLIGHTS
SUMMARY
Reduced levels of miR-101 in the AD brain are reported, consistent with in_vitro studies in which miR-101 inhibition increased APP levels (Siedlecki-Wullich et_al, 2021). CUR has been reported in in_vitro studies to inhibit Aβ aggregation and Aβ-induced inflammation, as well as β-secretase and acetylcholinesterase activity (Ono et_al, 2004; Ahmed and Gilani, 2009; Sokolik and Shulga, 2016). In in_vivo studies, oral or nasal administration of CUR resulted in inhibition of Aβ deposition, Aβ oligomerization, and tau phosphorylation in the brain of AD animal models, as well as improvement in behavioral disturbances . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.